331160 RESULTS
COMMENT What could possibly go wrong with the use of BACE inhibitors for the prevention or treatment of AD? The latest flurry of results from pharmaceutical companies showing that BACE inhibitors reduce the levels of amyloid-β in the brain has led to a renewed wa
COMMENT When looking in PubMed, one sees that there is an exponential increase in the number of studies on biomarkers for AD, and the opportunities should be excellent for making meta-analyses on the topic. However, if one sets out to curate the literature, it wi
MedicineGermany
CONFERENCE COVERAGE 2012-08-03 Conference Coverage Most researchers agree that clinical dementia papers need reporting standards, especially when it comes to diagnostic tests. Say you are interested in this question: How well does a given biomarker predict Alzheimer’s disease (AD), or
WEBINAR 2012-08-03 Scientists have uncovered hundreds of genetic variants that purportedly cause familial forms of various neurodegenerative diseases, including Alzheimer’s, Parkinson’s, frontotemporal dementias, and amyotrophic lateral sclerosis. But are all of these assoc
PAPER Mandemakers W, Snellinx A, O'Neill MJ, de Strooper B
PAPER Otomo A, Pan L, Hadano S
PAPER Chacón PJ, Rodríguez-Tébar A
PAPER Morgan CD, Murphy C
PAPER Dhikav V, Anand KS
PAPER Bell RD
PAPER Ambrose CT
PAPER
PAPER Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S
PAPER Giunta B, Obregon D, Velisetty R, Sanberg PR, Borlongan CV, Tan J
No filters selected
